Lineage Cell Therapeutics Inc (LCTX) — Cash Flow Reinvestment Rate
Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow Reinvestment Rate of 0.00x as of March 2022, reinvesting $92.00K (capex $46.00K plus investments $-46.00K) from operating cash flow of $21.90 Million. Explore LCTX capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Lineage Cell Therapeutics Inc Cash Flow Reinvestment Rate (2022–2022)
Historical reinvestment intensity for Lineage Cell Therapeutics Inc across 1 annual periods. Also explore balance sheet size of Lineage Cell Therapeutics Inc for the complete picture of this company's asset base.
Annual Cash Flow Reinvestment Rate for Lineage Cell Therapeutics Inc (2022–2022)
Year-by-year capital reinvestment analysis for Lineage Cell Therapeutics Inc. For live market cap and broader valuation context, see Lineage Cell Therapeutics Inc (LCTX) total market value.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 43.59x | $46.16 Million | $1.06 Million | $413.00K | — |